

The CDRH home page may be accessed at <http://www.fda.gov/cdrh>. "Guidance on Medical Device Patient Labeling" will be available at <http://www.fda.gov/cdrh/HumanFactors.html>.

IV. Comments

Interested persons may submit to the Dockets Management Branch (address above) written comments regarding the guidance at any time. Such comments will be considered when determining whether to amend the current guidance. Two copies of any comments are to be submitted, except that individual may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. The guidance document is available for public examination in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

Dated: April 2, 2001.

Linda S. Kahan,

*Deputy Director for Regulations and Policy,
Center for Devices and Radiological Health.*
[FR Doc. 01-9652 Filed 4-18-01; 8:45 am]

BILLING CODE 4160-01-S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Request for Chimpanzee Sanctuary Capability Statements

The purpose of this Notice is to determine the capabilities of any private nonprofit organizations interested in serving as a contractor to provide lifetime care for chimpanzees as required under the "Chimpanzee Health Improvement, Maintenance, and Protection (CHIMP) Act," Public Law 106-551, which amended Section 481C of the Public Health Service Act on December 20, 2000.

To carry out the CHIMP Act, the National Institutes of Health (NIH), acting on behalf of the Secretary of Health and Human Services, will, among other things:

- Seek to award a contract to a private nonprofit organization that meets the detailed requirements set forth in the Act. A complete copy of the Act is available at <http://thomas.loc.gov/> or from the Contract Office listed below. Interested institutions should pay particular attention to the sections titled "Chimpanzees Accepted Into System" [Section 481C(d)(2)(A)-(K)], "Requirements" [Section 481C(e)(2)(A)-(H)], "Board of Directors" [Section 481C(e)(3)], and "Requirement of

Matching Funds" [Section 481C(e)(4)]; and

- Identify the number of chimpanzees no longer needed for research that are available for placement in the sanctuary.

In order for NIH to assess those organizations capable of responding to a Request for Proposals, we are requesting that interested organizations submit capability statements. When responding to this notice, organizations are asked to review the requirements of the CHIMP Act and address the following 5 items:

1. *Nonhuman Primate Management Experience and Stability:* (a) Describe when your organization was established; (b) its management structure; (c) the staff that would be assigned to this project; (d) their experience in managing and caring for chimpanzees; (e) evidence of financial stability and resources that can be brought to the project;

2. *Matching Funds:* Provide evidence of your organization's ability to make non-Federal contributions in cash or in-kind, in an amount not less than 10% of the establishment costs (including construction costs), and 25% of the yearly operational expenses;

3. *Capacity to Hold Chimpanzees:* Due to cost effectiveness constraints aimed at achieving the savings foreseen by the Congressional Budget Office, potential offerors must demonstrate the capacity to house and care for at least 75 chimpanzees. Describe your facility's present or planned capacity to manage and operate a system holding at least 75 chimpanzees, with the future possibility of expansion at the original or additional sites;

4. *Working with Diverse Groups:* Describe your ability and willingness to work with members of the animal protection community, NIH, and a wide variety of other interested parties. In addition, describe your experience or plans for using a board of directors experienced in captive chimpanzee management, animal protection, behavioral primatology, business management, laboratory animal medicine, accreditation of animal facilities, and biohazard containment;

5. *Board of Directors:* Submit letters of commitment for possible members to serve on the board of directors of the sanctuary. Indicate the full name, credentials, expertise, and organizational affiliation(s) for each person.

If possible, please address the 5 items above in a capability statement of no more than 30 pages in length. The capability statement will neither bind nor obligate any organization at this time. If a Request for Proposals (RFP) is issued, the NIH will transmit a copy of

it to all organizations whose capability statements have been received by the due date of May 15, 2001. An announcement of availability of the RFP will also be made in the Commerce Business Daily and in the NIH Guide for Grants and Contracts. Please send three copies of the capability statement with an accompanying signed transmittal letter so that they will be received at the following address by May 15, 2001: Mr. Robert Best, Contracting Officer, National Heart, Lung, and Blood Institute, DEA, Contracts Operations Branch, Two Rockledge Centre, Room 6100, 6701 Rockledge Drive, MSC 7902, Bethesda, MD 20892-7902.

Dated: April 12, 2001.

Ruth L. Kirschstein,

Acting Director, NIH.

[FR Doc. 01-9681 Filed 4-18-01; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel, Spore in Breast and Prostate Cancer.

Date: May 9-10, 2001.

Time: 8 a.m. to 6 p.m.

Agenda: To review and evaluate grant applications.

Place: Radisson Barcelo Hotel, 2121 P Street, NW, Washington, DC 20037.

Contact Person: Brian E. Wojcik, PhD, Scientific Review Administrator, Grants Review Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Boulevard, Room 8019, Bethesda, MD 20892, 301/402-2785.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when

applicable, the business or professional affiliation of the interested person.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: April 10, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 01-9693 Filed 4-18-01; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel, Technologies for Comprehensive, Quantitative Protein Analysis in Human Tumors.

Date: May 7-8, 2001.

Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: Holiday Inn, 8120 Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: Joyce C Pegues, PhD, Scientific Review Administrator, Special Review, Referral, and Resources Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Boulevard, Room 8084, Bethesda, MD 20892, 301/594-1286.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399,

Cancer Control, National Institutes of Health, HHS)

Dated: April 10, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 01-9695 Filed 4-18-01; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel, Cancer Care Outcomes Research and Surveillance Consortium.

Date: April 30-May 1, 2001.

Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: Ramada Inn Rockville, 1775 Rockville Pike, Rockville, MD 20852.

Contact Person: Lalita D. Palekar, PhD, Scientific Review Administrator, Special Review, Referral and Resources Branch, Division of Extramural Activities, National Cancer Institute, National Institute of Health, 6116 Executive Boulevard, Room 8066, Bethesda, MD 20892-7405, (301) 496-7575.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: April 10, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 01-9696 Filed 4-18-01; 8:45 am]

BILLING CODE 41-10-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the President's Cancer Panel.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

Name of Committee: President's Cancer Panel.

Date: May 24-25, 2001.

Time: 9 a.m. to 3 p.m.

Agenda: Improving Cancer Care for All: Real People—Real Problems.

Place: Grand Hyatt, 1000 H Street, NW, Washington, DC 20001.

Contact Person: Maureen O. Wilson, PhD, Executive Secretary, National Cancer Institute, National Institutes of Health, 31 Center Drive, Building 31, Room 4A48, Bethesda, MD 20892, 301/496-1148.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute's/Center's home page: deainfo.nci.nih.gov/advisory/pcp/pcp.htm, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: April 10, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 01-9697 Filed 4-18-01; 8:45 am]

BILLING CODE 4140-01-M